Dr. Thomas A. Albini, MD

Dr. Albini practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Albini's NPI, 1831106079, was assigned on August 1, 2006. Dr. Albini graduated from The Johns Hopkins University School of Medicine in 1999. Dr. Albini holds Florida license ME95348.

Dr. Albini's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Albini's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. Dr. Albini is also affiliated with Baptist Health Baptist Hospital. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Albini to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Albini practices, 3 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Albini's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Albini is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Albini's licenses on file in 3 states: Florida, California and Texas.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, dry eye, eyelid inflammation, glaucoma, hypertensive retinopathy and inflammation of iris among the conditions Dr. Albini treats.

CMS data shows 2,520 Medicare services from Dr. Albini across 7 procedure codes in 2024, for 463 Medicare patients. Medicare paid $118,979 for them.

CMS counts 463 Medicare patients who saw Dr. Albini in 2024. The largest group is 75 to 84, with 201 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Albini's median patient age at 71, with 57% women.

In 2024, Dr. Albini wrote 2,463 Medicare Part D claims for 376 patients. 61% of them were for generic drugs. CMS names the drug for 2,327 of them, across 28 drugs with 11 or more claims each, at $594,480 in total drug cost. In 2023, CMS named 2,242 claims across 26 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Albini for performance year 2024, reported as part of a group. Dr. Albini accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 13 procedures of cataract surgery by Dr. Albini, more than 36% of the clinicians it reports for that procedure.

Dmand AI links 177 papers to Dr. Albini, published from 2006 to 2025. 2019 was the busiest year, with 12. The most frequent topics are Visual Acuity, Tomography, Optical Coherence and Vitrectomy. Dr. Albini has published most often in Ophthalmic Surg Lasers Imaging Retina. Dr. Albini's most frequent co-authors are Harry W. Flynn, MD, Janet L. Davis, MD and Jayanth Srinivasan-Kasi Sridhar, MD.

Dmand AI links Dr. Albini to 1 clinical trial. Conditions studied include Uveitis and Macular Edema.

CMS Open Payments shows 460 general payments to Dr. Albini from 38 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 83% of the total. Novartis Pharmaceuticals Corporation paid the most, $98,043. It also lists 10 research payments totaling $44,578 from 2016 to 2021.

Dmand AI lists 3 awards for Dr. Albini, most recently Super Doc in 2014.

Dr. Albini graduated from The Johns Hopkins University School of Medicine in 1999.

Dr. Albini is in network with 11 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.